Parkinson Protein 7 (PARK7) antibody

Antigen: Parkinson Protein 7 (PARK7)

Synonyms: DJ1, DJ-1, FLJ27376, FLJ34360, FLJ92274

Clonality: Polyclonal

Host: Rabbit

Reactivity: Human, Cow (Bovine), Mouse (Murine), Rat (Rattus)

Application: ELISA, Western Blotting (WB), Immunoprecipitation (IP)

Catalog no.: ABIN129620

Additional Information

Alternative name: PARK-7

Gene ID: NP_009193

Swiss-Prot: Q99497

Immunogen: This affinity purified antibody was prepared from whole rabbit serum produced by repeated immunizations with asynthetic peptide corresponding aa 177-189 of Human PARK7 protein.

Format: Liquid (sterile filtered)

Description: The product of the PARK7gene, known as PARK7, Parkinson disease(autosomal recessive, early onset) 7, DJ-1 mutant, andDJ-1 oncogene product, functions as a positiveregulator of androgen receptor-dependenttranscription. PARK7 may also function as a redox-sensitive chaperone and as a sensor for oxidativestress and also has been reported to preventaggregation of SNCA. PARK7 protects neuronsagainst oxidative stress and cell death and plays a rolein fertilization. While PARK7 has no proteolytic activity,it does have a weak transforming activity. PARK7forms a homodimer and binds to DJBP and PIAS2.PARK7 is part of a ternary complex containing PARK7,DJBP and AR and shows both a nuclear andcytoplasmic localization. In some cells, PARK7 isassociated with mitochondria, particularly after oxidative stress. This protein is highly expressed in pancreas, kidney, skeletal muscle, liver, testis and heart tissue, and isexpressed at lower levels in placenta and brain. PARK7 is detected in tau inclusions in brains from neurodegenerativedisease patients, in astrocytes, Sertoli cells, spermatogonia, spermatids and spermatozoa. Defects in PARK7 are the cause ofautosomal recessive early-onset Parkinson's disease 7 (PARK7). Parkinson's disease (PD) is a complex, multifactorialdisorder that is characterized by bradykinesia, resting tremor, muscular rigidity and postural instability, response to treatmentwith levodopa, the loss of dopaminergic neurons in the substantia nigra and the presence of Lewy bodies (intraneuronalaccumulations of aggregated proteins) in surviving neurons.

Specificity: This is an affinity purified antibody produced by immunoaffinity chromatography using theimmunizing peptide after immobilization to a solid phase. Reactivity occurs against human PARK7 protein. BLAST analysiswas used to determine that 100% homology with the immunizing peptide sequence is on record for this protein from human,chimpanzee, African green monkey, zebrafish and also for mutant/variant forms of human DJ-1 protein. Cross reactivity withPARK7 from frog, mouse, rat, dog, chicken, Japanese rice fish and Atlantic salmon may also occur as the sequence varies byonly one amino acid residue as indicated by BLAST analysis. Reactivity with PARK7 protein from other sources is not known. Protein Sequence: Human PARK7, 189 aa, predicted MW 19.9 kDa 1 maskralvil akgaeemetv ipvdvmrrag ikvtvaglag kdpvqcsrdv vicpdasled 61 akkegpydvv vlpggnlgaq nlsesaavke ilkeqenrkg liaaicagpt allaheigfg 121 skvtthplak dkmmngghyt ysenrvekdg liltsrgpgt sfefalaive alngkevaaq 181 vkaplvlkd General

Application Details

Application Notes: This affinity purified antibody has been tested for use in ELISA, immunohistochemistry and westernblot. Specific conditions for reactivity should be optimized by the end user. Expect a band approximately 28 kDa in sizecorresponding to PARK7 by western blotting in the appropriate cell lysate or extract. Dilutions: ELISA 1:10,000 - 1:50,000 WESTERN BLOT 1:500 - 1:2,000 IMMUNOHISTOCHEMISTRY 2 ug/ml - 5 ug/ml OTHER APPLICATIONS User Optimized

Concentration: 1.3 mg/ml (by UV absorbance at 280 nm)

Buffer: Stabilizer: None. Preservative: 0.01% (w/v) Sodium Azide. Buffer: 0.02 M Potassium Phosphate, 0.15 M Sodium Chloride, pH 7.2.

Storage: Store vial at -20° C prior to opening. Dilute only prior to immediate use. For extended storage aliquotcontents and freeze at -20° C or below. Avoid cycles of freezing and thawing. Expiration date is one (1) year from date ofopening.

Restrictions: For Research Use only

Images

Western blot analysis is shown using antibodies-online's Affinity Purified anti-Human PARK7 antibody to detect PARK7 present in Jurkat whole cell lysate. This western blot shows reactivity with human PARK7 protein. Comparison to a molecular weight marker indicates a predominant band of ~28.0 kDa. Peptide competition blocks specific reactivity of the antibody with PARK7 (not shown). A 16% Tris-Tricine gel was used to separate proteins prior to transfer to 0.2 uM nitrocellulose. The blot was incubated with a 1:1,300 dilution of the antibody overnight at 4

Immunohistochemistry. antibodies-online's Affinity Purified anti-PARK7 antibody was used at a 5 ug/ml to detect PARK7 in a variety of tissues. In some tissues elevated background staining was noted. In these instances further optimization of dilution is suggested. This image shows PARK7 staining of human pancreas. Tissue was formalinfixed and paraffin embedded. Personal Communication, Tina Roush, LifeSpanBiosciences, Seattle, WA.